Vector-carried polypeptide(s), wherein said vector carrying the polypeptide(s) consists in an adenylcyclase protein of a Bordetella species CyaA protein or a fragment thereof suitable to present said polypeptide(s) to the immune system in a mammalian host, for use: (i) in the immunotherapeutic treatment of first determined pathological condition(s) which is (a) consecutive to infection by a first HPV strain selected among HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV52 or HPV58 or (b) related to a tumor expressing MAGE-A3 antigen diagnosed in said mammalian host wherein said treatment is by eliciting a T cell immune response against a first group of epitopes contained in said polypeptide(s) and wherein in (a) the epitopes of said first group are from E6 or E7 antigens of an HPV strain selected among HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV52 or HPV58 or respectively in (b) the epitopes of said first group are from a MAGE-A3 tumor antigen and (ii) in the prophylaxis against second determined pathological condition(s) wherein when said first pathological condition is consecutive to HPV infection as in (a), said second pathological condition is consecutive to infection by a second HPV strain different from the first one and said different HPV is selected among HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV52 or HPV58 or wherein said second determined condition is related to a tumor expressing MAGE-A3 antigen, wherein said second pathological condition is in the same mammalian host and a T cell memory immune response is elicited against a second group of epitopes contained in said polypeptide(s) and wherein in said second group the epitopes are from an antigen of the second HPV selected among HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV52 or HPV58 or respectively from a MAGE-A3 tumor antigen, said immune responses being obtained after administration of said vector-carried polypeptide(s) into said host, wherein said prophylaxis against second determined pathological condition(s) is not observed when said second group of epitopes is not contained in said administered vector-carried polypeptide(s) and wherein the amino acid sequence of said first group of epitope is different from the amino acid of said second group of epitopes. (i) in the immunotherapeutic treatment of first determined pathological condition(s) which is (a) consecutive to infection by a first HPV strain selected among HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV52 or HPV58 or (b) related to a tumor expressing MAGE-A3 antigen diagnosed in said mammalian host wherein said treatment is by eliciting a T cell immune response against a first group of epitopes contained in said polypeptide(s) and wherein in (a) the epitopes of said first group are from E6 or E7 antigens of an HPV strain selected among HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV52 or HPV58 or respectively in (b) the epitopes of said first group are from a MAGE-A3 tumor antigen and (ii) in the prophylaxis against second determined pathological condition(s) wherein when said first pathological condition is consecutive to HPV infection as in (a), said second pathological condition is consecutive to infection by a second HPV strain different from the first one and said different HPV is selected among HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV52 or HPV58 or wherein said second determined condition is related to a tumor expressing MAGE-A3 antigen, wherein said second pathological condition is in the same mammalian host and a T cell memory immune response is elicited against a second group of epitopes contained in said polypeptide(s) and wherein in said second group the epitopes are from an antigen of the second HPV selected among HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV52 or HPV58 or respectively from a MAGE-A3 tumor antigen, said immune responses being obtained after administration of said vector-carried polypeptide(s) into said host, wherein said prophylaxis against second determined pathological condition(s) is not observed when said second group of epitopes is not contained in said administered vector-carried polypeptide(s) and wherein the amino acid sequence of said first group of epitope is different from the amino acid of said second group of epitopes.